Glioma
Conditions
Keywords
Glioma; 11C-Methionine PET
Brief summary
This is a retrospective study that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of maximum 145 patients with glioma treated with surgery with radical intent at our center.
Detailed description
This is a retrospective observation that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of 145 patients with glioma treated with surgery with radical intent at our center. We will review 11C-Methionine PET data acquired within 30 days prior to surgery and analyze its principal imaging characteristics with respect to IDH1 mutation status, MGMT promoter methylation and 1p/19q co-deletion. These markers will be studied on tumor tissue obtained at surgery, used for diagnostic purposes and stored in paraffin.
Interventions
OTHERNo intervention
This is a retrospective study
Sponsors
Istituto Clinico Humanitas
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of glioma * 11C-Methionine within 30 days before surgery
Exclusion criteria
* Absence of tumor specimen * No clinical data * 11C-Methionine can not be evaluated
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation of SUVmax (Maximal Standardized Uptake Value) in patients with glioma undergoing surgery with IDH1 mutation, MGMT promoter methylation and 1p/19q co-deletion, | Baseline SUVmax up to 1 month before surgery. |
Countries
Italy
Outcome results
None listed